When vaginal diseases occur, they frequently cause significant discomfort, disruption of daily activities, and anxiety. Vaginal conditions range from common infections such as bacterial vaginosis and vulvovaginal candidiasis to dermatologic disorders, hormonal atrophy, and sexually transmitted infections. Understanding the multiple factors that predispose to these conditions helps clinicians provide accurate diagnosis, effective treatment, and appropriate prevention counseling.

This article reviews the anatomy and defenses of the lower female genital tract, outlines the major infectious and noninfectious causes of vaginal disease, explores behavioral and systemic risk factors, and summarizes diagnostic and management principles. Recommendations and background are drawn from the American College of Obstetricians and Gynecologists (ACOG), the National Institutes of Health (NIH/MedlinePlus), the Mayo Clinic, and the Cleveland Clinic.

Vaginal anatomy, microbiology, and defense mechanisms

A clear understanding of normal vaginal anatomy and physiology helps explain why certain exposures and conditions predispose to disease.

  • The vagina is a muscular mucosal canal lined by stratified squamous epithelium. It is closely related to the vulva anteriorly and to the cervix and uterus superiorly.
  • The vaginal ecosystem is dominated by Lactobacillus species in many healthy individuals. Lactobacilli produce lactic acid and hydrogen peroxide, maintaining an acidic vaginal pH (typically <4.5) that inhibits overgrowth of many pathogens (ACOG; Mayo Clinic).
  • Vaginal secretions, epithelial turnover, local immune responses, and the mucous of the cervix all contribute to protection against infection.
  • Disruptions of the microbiome, changes in pH, or impairment of local immunity increase susceptibility to infection and inflammatory conditions (ACOG; NIH).

(References: ACOG patient education and practice bulletins; NIH MedlinePlus; Mayo Clinic overview of vaginal infections.)

Common infectious causes

Bacterial vaginosis (BV)

  • Etiology and pathophysiology: BV represents an imbalance of the vaginal microbiota, characterized by depletion of protective lactobacilli and overgrowth of mixed anaerobic bacteria (e.g., Gardnerella vaginalis, Prevotella spp., Mobiluncus) (ACOG; NIH).
  • Risk factors: new or multiple sexual partners, frequent intercourse (without barrier protection), intrauterine devices in some studies, douching, recent antibiotic use, and smoking have all been associated with increased BV risk (Mayo Clinic; Cleveland Clinic).
  • Clinical features: many women are asymptomatic. When present, symptoms include a thin, homogeneous vaginal discharge with a characteristic fishy odor, particularly after intercourse. Vaginal pH is typically >4.5.
  • Diagnosis: clinical criteria (Amsel’s criteria) or gram-stain scoring (Nugent score) can be used; nucleic acid amplification tests (NAATs) are increasingly available.
  • Treatment: recommended regimens include oral or topical metronidazole or topical clindamycin. Recurrent BV is common and may require longer or suppressive therapies (ACOG; Mayo Clinic).
  • Complications: BV is associated with an increased risk of pelvic inflammatory disease (PID), adverse pregnancy outcomes, and increased susceptibility to some sexually transmitted infections (STIs) (NIH).

Vulvovaginal candidiasis (yeast infection)

  • Etiology: most commonly caused by Candida albicans; non-albicans species can also be implicated.
  • Risk factors: recent systemic antibiotic use, poorly controlled diabetes mellitus (hyperglycemia promotes fungal growth), pregnancy, immunosuppression, and prolonged corticosteroid or immunosuppressive therapy increase risk (Mayo Clinic; Cleveland Clinic).
  • Clinical features: intense vulvovaginal itching, burning, vulvar erythema and swelling, and thick, white, “cottage cheese”–like discharge are typical. pH is usually normal (<4.5).
  • Diagnosis: microscopy (wet mount with potassium hydroxide), culture or molecular testing when recurrent or atypical.
  • Treatment: topical azole antifungals (e.g., clotrimazole, miconazole) or a single oral dose of fluconazole are commonly used. Recurrent vulvovaginal candidiasis often requires longer antifungal courses and investigation for predisposing factors such as diabetes (ACOG; Mayo Clinic).

Trichomonas vaginalis (trichomoniasis)

  • Etiology: a protozoan parasite transmitted primarily through sexual contact.
  • Risk factors: unprotected sexual exposure and presence of other STIs increase risk.
  • Clinical features: variable—many individuals are asymptomatic. Symptoms may include frothy, malodorous discharge, vulvar irritation, and dyspareunia. Vaginal pH is typically >4.5.
  • Diagnosis: NAATs are more sensitive than microscopy and are the preferred diagnostic methods when available.
  • Treatment: single or multi-day regimens of oral metronidazole or tinidazole; sexual partners should be treated simultaneously to prevent reinfection (ACOG; NIH).

Sexually transmitted infections affecting the lower genital tract

  • Chlamydia trachomatis and Neisseria gonorrhoeae: commonly cause cervicitis and can lead to pelvic inflammatory disease if untreated. These infections may present with vaginal discharge, intermenstrual bleeding, pelvic pain, or be asymptomatic. Screening is recommended for sexually active young women and other at-risk populations (ACOG; NIH).
  • Genital herpes simplex virus (HSV): recurrent painful vulvar or perineal lesions may occur; systemic antiviral therapy can reduce symptom duration and shedding.
  • Human papillomavirus (HPV): certain HPV types cause genital warts, whereas high-risk types are associated with cervical and vulvar neoplasia; HPV vaccination reduces the risk of infection with high-risk strains (ACOG; NIH).
  • Note: barrier protection (e.g., condoms) reduces but does not eliminate the risk of acquiring infections that can affect vulvovaginal tissues.

Noninfectious causes

Not all vulvovaginal symptoms stem from infections. Dermatologic, hormonal, allergic, and structural conditions also contribute.

Allergic and irritant contact dermatitis

  • Many topical products can provoke either irritant or allergic dermatitis of the vulva and vulvovaginal tissues: fragranced soaps, bubble baths, spermicides, lubricants with additives, laundry detergents, latex in barrier methods, and preservatives.
  • Clinical features: burning, stinging, erythema, and variable discharge if secondary infection occurs.
  • Management: identify and discontinue the offending agent; topical emollients, avoidance strategies, and short courses of topical low‑potency corticosteroids can be useful under clinical supervision (Cleveland Clinic; Mayo Clinic).

Atrophic vaginitis / genitourinary syndrome of menopause (GSM)

  • Etiology: estrogen deficiency in perimenopause and menopause leads to thinning of vaginal mucosa, decreased elasticity, reduced secretions, and a higher pH—predisposing to irritation, recurrent infections, and dyspareunia.
  • Management: nonhormonal lubricants and moisturizers; local vaginal estrogen therapy is highly effective for symptomatic relief and restoration of the vaginal environment in appropriate candidates (ACOG; NIH).

Lichen sclerosus, lichen planus, and other vulvar dermatoses

  • These chronic inflammatory conditions can cause vulvar thinning, scarring, itching, pain, and dyspareunia. They may require biopsy for diagnosis.
  • Treatment typically includes topical high-potency corticosteroids for lichen sclerosus and specialist-directed therapy for lichen planus; long-term follow-up is often necessary (ACOG; Cleveland Clinic).

Vulvodynia and persistent pelvic pain syndromes

  • Vulvar pain without an identifiable dermatologic or infectious cause can be chronic and multifactorial (neuropathic, muscular, inflammatory). Management is multidisciplinary, including pelvic floor physical therapy, topical therapies, and pain management techniques (Mayo Clinic).

Systemic and medical risk factors

Metabolic and immunologic states

  • Diabetes mellitus: hyperglycemia both impairs immune function and increases glucose in vaginal secretions, favoring candidal overgrowth.
  • Immunosuppression: conditions such as HIV infection, systemic corticosteroid therapy, chemotherapy, or other immunosuppressant drugs increase susceptibility to opportunistic infections and atypical presentations (NIH; ACOG).

Medications

  • Antibiotics: broad‑spectrum systemic antibiotics commonly reduce lactobacilli and alter vaginal flora, increasing the risk of both candidiasis and bacterial vaginosis.
  • Hormonal contraceptives: combined estrogen–progestin contraceptives may influence the vaginal milieu; data are variable with respect to effects on BV risk. Spermicidal products (nonoxynol-9) can disrupt mucosal integrity and increase susceptibility to STIs in some settings (Cleveland Clinic).
  • Topical products: inappropriate or prolonged use of topical steroid agents without medical supervision can thin vulvar skin and mask other conditions.

Pregnancy

  • Pregnancy is associated with increased vaginal discharge, changes in pH, higher glycogen content of vaginal epithelium (which may favor Candida), and immunologic modulation. These factors increase the risk of BV and candidiasis and complicate treatment choices (ACOG; Mayo Clinic).

Behavioral and environmental contributors

  • Douching: intentionally irrigating the vagina with water or antiseptic solutions disrupts the natural flora and pH, and is associated with increased risk of BV, pelvic inflammatory disease, and adverse pregnancy outcomes. Routine douching is not recommended (ACOG; NIH).
  • Clothing: tight, non-breathable clothing and synthetic underwear can trap moisture and heat, creating an environment that favors fungal overgrowth and irritation. Cotton underwear and loose-fitting clothing promote ventilation.
  • Hygiene practices: vigorous scrubbing, use of perfumed products, and harsh soaps can cause irritation or allergic reactions. Gentle genital hygiene with water and mild, fragrance‑free cleansers is preferred.
  • Menstrual practices and tampon use: prolonged retention of tampons or pads without changing can increase moisture and irritation; however, normal tampon use per instructions is not a primary cause of most vaginal infections. Proper hygiene and regular changing of menstrual products are advised.

Devices and contraception

  • Intrauterine devices (IUDs): some studies have suggested an association between IUDs and BV, while others do not. IUDs are not a major independent cause of the most common vaginal infections but may be associated with alterations in flora in some individuals.
  • Barrier methods: condoms reduce transmission of many STIs and help prevent infections that may involve the vulvovaginal tissues. However, latex allergy or sensitivity to condom lubricants can cause local irritation in susceptible individuals.
  • Spermicides and diaphragms: spermicidal agents can disturb mucosal flora and increase irritation in some cases.

Diagnosis: clinical evaluation and testing

A thorough clinical assessment is essential for accurate diagnosis.

  • Medical history: onset and character of symptoms, recent antibiotic use, sexual history, contraceptive use, menstrual and pregnancy status, diabetes, use of topical products, and prior similar episodes.
  • Physical examination: external vulvar inspection, speculum examination to assess discharge and the vaginal mucosa, and bimanual examination if indicated.
  • Office testing: vaginal pH measurement, potassium hydroxide (KOH) wet prep for budding fungi, saline wet mount for motile trichomonads, and amine (whiff) test may assist in differentiating causes.
  • Laboratory testing: NAATs for chlamydia, gonorrhea, and trichomonas are preferred when available; culture or PCR can identify Candida species if recurrent or refractory; Gram stain with Nugent scoring is used in research/clinical labs for BV.
  • Biopsy: indicated for suspicious vulvar lesions or when dermatologic disease is suspected.
  • Referral: recurrent or refractory cases, dermatologic disorders, cryptic lesions, or concern for neoplasia warrant specialist referral (gynecologist or vulvar dermatology).

(References: ACOG practice bulletins; NIH MedlinePlus; Mayo Clinic; Cleveland Clinic.)

Treatment principles

Management should be etiology-directed, consider patient preferences, and account for pregnancy and comorbidities.

  • Infections:
  • BV: oral or topical metronidazole or topical clindamycin courses; for recurrent BV, suppression or maintenance regimens can be considered under clinical guidance (ACOG).
  • Candidiasis: topical azoles for 1–7 days or single oral fluconazole dose; recurrent cases may require prolonged therapy and evaluation for diabetes or immunosuppression (Mayo Clinic).
  • Trichomoniasis: oral metronidazole or tinidazole; treat sexual partners and avoid alcohol with nitroimidazole treatment per prescribing instructions (NIH).
  • STIs (chlamydia, gonorrhea, HSV): follow current clinical guidelines for appropriate antimicrobial and antiviral therapy; reportable infections may require public health notification and partner management (ACOG; NIH).
  • Noninfectious conditions:
  • Allergic/irritant dermatitis: avoidance of offending agents, use of barrier emollients, and short courses of topical low‑potency corticosteroids when needed.
  • GSM/atrophic vaginitis: vaginal moisturizers, lubricants for symptomatic relief; low-dose vaginal estrogen therapy when appropriate and in the absence of contraindications (ACOG).
  • Vulvar dermatoses: high-potency topical corticosteroids for lichen sclerosus; immunomodulators and specialty care for lichen planus and other dermatoses.
  • Adjunctive therapies and prevention:
  • Probiotics: oral or vaginal lactobacilli-containing products are used by some patients to restore flora; evidence is mixed and remains an area of active research. Discuss use with a clinician before initiating, particularly for recurrent disease (Cleveland Clinic; NIH).
  • Glycemic control: optimizing blood glucose in persons with diabetes reduces risk of candidal infections.
  • Discontinuation of unnecessary antibiotics or topical irritants.

Prevention strategies

  • Avoid douching and fragranced genital products.
  • Use breathable cotton underwear and avoid persistent tight clothing.
  • Change out of wet clothes promptly (e.g., after exercise or swimming).
  • Practice safe sexual behaviors, including use of barrier protection and mutual monogamy or partner testing when appropriate.
  • Maintain good chronic disease control (e.g., diabetes) and discuss the impact of medications on vaginal health with providers.
  • Receive age‑appropriate vaccinations (e.g., HPV vaccination) and adhere to recommended STI screening guidelines.
  • Seek timely medical attention for symptoms rather than self‑treating with over-the-counter agents when the diagnosis is uncertain or symptoms are severe.

(References: ACOG patient education; Mayo Clinic; Cleveland Clinic.)

When to seek medical attention

Prompt evaluation is recommended when any of the following occur:

  • Severe symptoms such as intense pain, fever, or systemic symptoms.
  • New or unusual vaginal bleeding, especially between periods or after intercourse.
  • Suspicious lesions, ulcers, or persistent vulvar irritation.
  • Recurrent infections (e.g., more than four episodes of vulvovaginal candidiasis per year).
  • Pregnancy with any symptomatic vaginal infection.
  • Immunocompromised persons experiencing new vulvovaginal symptoms.
  • Lack of response to standard over-the-counter treatments or worsening of symptoms.

Early clinical evaluation improves diagnostic accuracy and facilitates timely therapy, reducing the risk of complications.

Special considerations

  • Pregnancy: some commonly used medications are contraindicated; always consult obstetric care providers before initiating treatment. Untreated infections such as BV and trichomoniasis can increase adverse pregnancy risks.
  • Recurrent disease: recurrent BV and recurrent vulvovaginal candidiasis require thorough evaluation for underlying contributors (e.g., diabetes, re-exposure from untreated partners, contraceptive factors) and may benefit from specialist input.
  • Partner management: certain infections (e.g., trichomoniasis, chlamydia, gonorrhea, HSV) require evaluation and treatment of sexual partners to prevent reinfection and reduce onward transmission.

Summary

Vaginal diseases result from a complex interplay of microbiologic, immunologic, hormonal, behavioral, and environmental factors. Common infectious causes include bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis, while noninfectious etiologies include dermatologic conditions, allergic irritation, and genitourinary syndrome of menopause. Systemic conditions such as diabetes and immunosuppression increase susceptibility. Prevention emphasizes maintaining the normal vaginal environment (avoiding douching and irritating products), general health measures (glycemic control, appropriate clothing, prompt change of wet garments), safe sexual practices, and judicious use of antibiotics. Accurate diagnosis relies on history, examination, and targeted testing; treatment should be pathogen-specific or tailored to the underlying noninfectious condition. Individuals with severe, persistent, recurrent, or pregnancy-related symptoms should seek prompt medical evaluation.

References and resources

  • American College of Obstetricians and Gynecologists (ACOG). Patient education materials and practice bulletins on vaginitis, sexually transmitted infections, and genitourinary syndrome of menopause. https://www.acog.org
  • National Institutes of Health / MedlinePlus. Vaginal infections and vaginitis overview. https://medlineplus.gov/vaginalinfections.html
  • Mayo Clinic. Vaginal yeast infection (vaginal candidiasis): symptoms and causes. https://www.mayoclinic.org/diseases-conditions/vaginal-yeast-infection
  • Cleveland Clinic. Vaginitis: types, symptoms, and treatment. https://my.clevelandclinic.org/health/diseases/17636-vaginitis

(For detailed, condition-specific treatment guidelines and up-to-date therapeutic recommendations, consult specialty society guidance and local public health resources.)